The National Academies

The National Academies: What You Need To Know About Infectious Disease

What You Need To Know About Infectious Disease

Biological Threats and Terrorism: Assessing the Science and Response Capabilities—Workshop Summary (2002)

In the wake of September 11th and recent anthrax events, our nation's bioterrorism response capability has become an imminent priority for policymakers, researchers, public health officials, academia, and the private sector. In a three-day workshop, convened by the Institute of Medicine’s Forum on Emerging Infections, experts from each of these communities came together to identify, clarify, and prioritize the next steps that need to be taken in order to prepare and strengthen bioterrorism response capabilities. From the discussions, it became clear that of utmost urgency is the need to cast the issue of a response in an appropriate framework to attract the attention of Congress and the public and garner sufficient and sustainable support for such initiatives. No matter how the issue is cast, numerous workshop participants agreed that there are many gaps in the public health infrastructure and countermeasure capabilities that must be prioritized and addressed in order to assure a rapid and effective response to another bioterrorist attack.

View This Source

Related Reports

Explore Other Topics

What do you know about infectious disease?

True or False: Major pharmaceutical companies have great interest in dedicating resources to the antibiotics market because these short-course drugs are more profitable than drugs that treat chronic conditions and lifestyle ailments, such as high blood pressure or high cholesterol.

  • Sorry, that’s incorrect.

    Drugs that treat chronic conditions and lifestyle ailments are more profitable. Modern medicine needs new kinds of antibiotics to treat drug-resistant infections, but antibiotic research and development are expensive, risky, and time-consuming.

  • Correct!

    Drugs that treat chronic conditions and lifestyle ailments are more profitable. Modern medicine needs new kinds of antibiotics to treat drug-resistant infections, but antibiotic research and development are expensive, risky, and time-consuming.